Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutated-CALR Peptide Vaccine in MPN
NCT05025488Phase 1Active, not recruiting
- Start
- Apr 2023
- Primary completion
- Mar 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mutant-calreticulin peptide vaccine in Myeloproliferative Neoplasm (MPN). Primary endpoint: Dose Limiting Toxicity at 32 weeks. Started Apr 2023; status: active, not recruiting.
02
Drugs
mutant-calreticulin peptide vaccine
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT05025488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025488.